* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Dish of the Day
Admissions:
None
Delistings:
None
What’s baking in the oven?
IPOs:**
14th January: Roundhouse Digital, an operational AI services business with complementary strategic treasury management (Ethereum denominated), has announced its intention to IPO onto AQSE. Offer details TBC and expected Admission date 27 January.
Market Movers:***
14 January: GlobalData (DATA.L) , the data, insight, and technology Company expects to submit its application to move to the Main Market from AIM and to take place on 5 March.
12th January: The Smarter Web Company (AQSE:SWC) announces its intention to cancel its Admission to trading of its ordinary shares on the Aquis Growth Market and seek Admission onto the Main Market. Subject to shareholder approval, the Cancellation and Admission are expected to take place on 3 February.
11th November: CVS Group (CVSG.L) announced its plan to move from AIM to the Main Market on 29 January, subject to FCA approval of a prospectus and the ordinary shares being admitted by the FCA to the Main Market. The Group does not intend to raise funds in connection with the move.
Reverse Takeovers:***
31st December: Ovoca (OVB.L) announced a reverse takeover of Tadeen, a UK-registered Company, which indirectly owns 100% of the Licences in Morocco, prospective for Copper and Silver through its wholly owned subsidiary, Horizons Mines SARL. Capital to be raised on Admission is £1.155m with an anticipated market capitalisation on Admission of approximately £4.9m. Expected Admission date is 28th January.
Banquet Buffet****
The mobile internet payment platform Company announces a trading update for the 12 months ended 31 December 2025, ahead of announcing FY25 Final Results in Q2. The Company recorded positive cash EBITDA of approximately $2.3m, a $2.5m improvement from the negative Cash EBITDA of FY24. The Company also expects the growth of Cash EBITDA to accelerate in FY26. The annual recurring revenue increased by 30% year-on-year to $18.2m, driven by almost 60% growth in active subscriptions managed by the Digital Vending Machine.
Crism Therapeutics Corp 10.25p £5.17m (CRTX.L)
The UK clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs announces that it has been granted a patent by the Japanese Patent Office. The patent relates to the Company's lead product, ChemoSeed, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan. ChemoSeed was invented by Professor Chris McConville, CRISM's Chief Scientific Officer. The patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as glioblastoma.
Eagle Eye Solutions 345p £89.59m (EYE.L)
The SaaS and AI technology Company that creates digital connections enabling personalised, real-time marketing at scale, provided an update on trading for the six months ended 31 December 2025. The Board believes that the Group will deliver adjusted EBITDA for full year FY26 comfortably ahead of current market expectations, with revenue of £45.1m and adjusted EBITDA of £5.9m. Annual Recurring Revenue for H1 increased 29% to £42.2m.
First Development Resources 2.75p £3.83m (FDR.L)
The UK-based, Australia-focused exploration Company with mineral interests in Western Australia and the Northern Territory, announced that it has applied for three new Exploration Licences in the Paterson Province of Western Australia. The new applications, E45/7205, E45/7206 and E45/7207, are located immediately to the east of the Company's existing Wallal Project licences and cover ground previously held by Rio Tinto Exploration. The licence applications are now being assessed by the Department of Mines, Petroleum and Exploration in Western Australia to ensure compliance with all regulatory requirements, including environmental and land use considerations.
Galileo Resources 0.90p £11.74m (GLR.L)
The Company is pleased to report on laboratory assays from the recent reverse circulation drilling completed on its 100% owned prospecting licence PL253 in the Kalahari Copperbelt Botswana. This follows from the Company's announcement of 1 September 2025 in which positive indications of intermittent visible copper mineralisation were reported at PL253. Results from hole QTRC014 identified a peak interval of 5m 0.34% Cu (including 1m 0.84% Cu) within the D'Kar Formation, successfully verifying copper oxide presence beneath sand cover. The Company also reported that the Botswana Department of Mines has granted renewal of PL253/2018 for a further two years to end 2027.
Mycelx Technologies Corporation 33.00p £6.94m (MYX.L)
The clean water and clean air technology Company updates on trading for FY December 2025, with profitability expected to significantly ahead market expectations. The EBITDA and profit before tax is expected to be in the region of $680,000, a 131% improvement over FY 2024, which includes a gain of $160,000 from the sale of its Saudi Arabia operations, and $520,000 without the gain, compared to market expectations of an EBITDA loss of $200,000. The FY cash is $860,000 and a further $4m cash is expected to be collected in Q1 2026.
Staffline Group 48.80p £54.74m (STAF.L)
The recruitment Group provided a trading update for the full-year ended 31 December 2025. Revenue is up 11.5% to £1,106.7m, largely driven by a significant new strategic partnership with a logistics provider and continued market share growth in the blue-collar sector. Gross profit and operating profit have increased by 10.6% and 28.3% respectively, exceeding market expectations. Net cash (pre-IFRS 16) was recorded at £1.5m, while the Group undergoes an ongoing share buyback programme of up to £7.5m, repurchasing a total consideration of £6.5m in FY 2025.
System1 Group 224.0p £27.28m (SYS1.L)
The Company helps marketers tap into consumers’ emotions to predict and improve the commercial impact of ads and ideas. Today’s trading report for Q3 to December 2025 states the platform revenue in Q3 was higher than the preceding two quarters, benefiting from increased Ad testing revenue in the UK and Europe and a recovery from the wider macroeconomic uncertainty in Q1. Revenue from new client wins grew by a comparable 10% contributing £7.4m of the £25.7m. These new clients contributed £7.4m of the £25.7m Platform Revenue of which a third of it in the US. The Group held net cash of £8.3m compared to £10.2m and following the £1.4m dividend payment in October.
Team Internet Group 50.40p £117.55m (TIG.L)
The global internet Company that generates recurring revenue from creating meaningful and successful connections: businesses to domains, brands to consumers, publishers to advertisers, announced a trading update for the financial year ended 31 December 2025. The Group expects to report gross revenue, net revenue and adjusted EBITDA towards the top end of the range of current analyst forecasts for FY25, with the
performance primarily driven by accelerated momentum in the Comparison and Domains, Identity and Software segments, alongside determined focus on cost discipline across all segments. Further to the Strategic Review announced on 11 November 2025, the Company also confirms that discussions in relation to a disposal of DIS are progressing well. The Board remains confident that any transaction would deliver a value-maximising outcome in excess of the Group's current market capitalisation.
Thruvision Group 1.05p £4.26m (THRU.L)
The provider of walk-through security technology announces that it has been notified by one of the Company's regional integration partners of a contract award which includes the deployment of Thruvision's technology in a South-East Asian mass transit security application. The award is expected to generate more than £1m in revenue for Thruvision. The award relates to the deployment of 20 Thruvision high-throughput people-screening systems for a major international rail-link. Delivery of the systems is expected to take place during the current quarter. An additional award is anticipated for support services in the next financial year.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.